SBP-101 is a proprietary polyamine analogue that accumulates in the pancreatic acinar cells due to its unique chemical structure. It was discovered by Professor Raymond J. Bergeron at the University of Florida College of Pharmacy. Laboratory studies suggest the primary mechanism of action of SBP-101 is driven by its enhanced uptake in pancreatic cancer cells and, potentially, other cancer cell types, resulting in disruption of normal polyamine metabolism. SBP-101 is also taken up preferentially by the exocrine pancreas, the liver and kidneys. Importantly, pancreatic islet cells, which secrete insulin and are structurally and functionally dissimilar to acinar cells, are not impacted by SBP-101. SBP-101 has demonstrated significant growth inhibition of transplanted human pancreatic cancer cells in animal models.